Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.
Explore this paper's citation graph
Summary
CAR-19 T cells preceded by low-dose chemotherapy induced remission of advanced-stage lymphoma, and high serum IL-15 levels were associated with the effectiveness of this treatment regimen, which will likely become an important treatment for patients with relapsed lymphoma.
- Type
- article
- Published
- 2017-03-14
- Cited by
- 515
- References
- 52
- Access
- Open access
- OpenAlex
- https://openalex.org/W2602369513
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:3803174
Keywords
Medicine, Fludarabine, Lymphoma, Chemotherapy, Chimeric antigen receptor
References
- Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells
- RAPID VISION LOSS ASSOCIATED WITH FLUDARABINE ADMINISTRATION IN THREE PATIENTS
- Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma.
- CAR therapy: the CD19 paradigm.
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.
- Construction and Pre-clinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor
- Design and Development of Therapies using Chimeric Antigen Receptor-Expressing T cells
- Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
- Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15.
- Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15
- Mini‐BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage‐refractory DLBCL
- Outcomes of patients with relapsed/refractory diffuse large B‐cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era
- Interleukin-15 in the treatment of cancer
- Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies.
- Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety
- Diffuse large B-cell lymphoma.
- Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ.
- Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
- Granzyme B-Induced Neurotoxicity Is Mediated via Activation of PAR-1 Receptor and Kv1.3 Channel
Cited by
- Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from nonacademic institutions 1-31 July 2015.
- Immunotherapy: DLBCL remissions driven by CARs
- Biopreservation Best Practices for regenerative medicine GMP manufacturing & focus on optimized biopreservation media
- How I treat double-hit lymphoma.
- Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.
- Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
- Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
- Redirecting T cells with Chimeric Antigen Receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia.
- Chimeric Antigen Receptor T-cell Therapies for Lymphoma
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- The Latest Advances in CAR T-Cell Therapy for Refractory and Relapsed Lymphomas and Leukemias
- Chimeric antigen receptor T-cell therapies for multiple myeloma.
- CAR T cell immunotherapy in hematology and beyond.
- Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse
- The potential for chemotherapy-free strategies in mantle cell lymphoma.
- Discovery and application of immune biomarkers for hematological malignancies
- Gene Therapy with the Sleeping Beauty Transposon System.
- IMPROVING NK CELL THERAPY FOR OSTEOSARCOMA
- Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL
- Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Related papers
- Combined fludarabine and cyclophosphamide pretreatment alleviated acute graft-versus-host disease
- [Minimal residual disease in follicular and mantle cell lymphoma. Detection using quantitative molecular monitoring of circulating lymphoma cells].
- Combination therapy of Fludarabine and Cyclophosphamide(FC) Combination Regimen in advance stage of Chronic Lymphocytic Leukemia
- Frequent epigenetic inactivation of Rb1 in addition to p15 and p16 in mantle cell and follicular lymphoma.
- Clonally related composite follicular lymphoma and mantle cell lymphoma with clinicopathologic features and biological implications.
- Coexisting follicular and mantle cell lymphoma with each having an in situ component: A novel, curious, and complex consultation case of coincidental, composite, colonizing lymphoma.
- Radioimmunotherapy with 131I‐rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma
- Improving outcomes in transplantation.